Precipio Stock (NASDAQ:PRPO)

Revenue Ownership Financials Chart Transcripts

Previous Close

$24.55

52W Range

$3.90 - $28.50

50D Avg

$23.67

200D Avg

$16.21

Market Cap

$43.80M

Avg Vol (3M)

$10.38K

Beta

1.12

Div Yield

PRPO Company Profile

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jun 30, 2017

Website

PRPO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 24	Dec 23	Dec 22
Diagnostic Testing	$15.96M	$12.40M	$4.21M
Service revenue, net	$39.17M	$26.49M	$8.01M

Fiscal year ends in Dec 24 | Currency in USD

PRPO Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$15.96M	$15.20M	$9.41M
Operating Income	$-4.22M	$-7.62M	$-12.80M
Net Income	$-4.29M	$-5.85M	$-12.20M
EBITDA	$-4.22M	$-4.32M	$-10.65M
Basic EPS	$-2.93	$-4.51	$-10.73
Diluted EPS	$-2.93	$-4.51	$-10.73

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 14, 25 | 5:00 PM

Q1 25May 15, 25 | 5:00 PM

Q4 24Mar 31, 25 | 5:00 PM

Peer Comparison

Ticker	Company
PLUR	Pluri Inc.
INTS	Intensity Therapeutics, Inc.
POCI	Precision Optics Corporation, Inc.
STRR	Star Equity Holdings, Inc.
MODD	Modular Medical, Inc.
RBOT	Vicarious Surgical Inc.
ITRM	Iterum Therapeutics plc